Abstract To investigate the cell-biological eVect of topically applied 5-Xuorouracil (5-FU) on middle ear cholesteatoma, 12 attic cholesteatomas were treated with topical application of 5-FU cream, two to Wve times with an interval of 2 weeks (5-FU group). The control group comprised 65 cholesteatoma that were not treated with 5-FU. All lesions were later excised surgically and processed for immunohistochemical analyses of Ki-67, keratinocyte growth factor (KGF) and its receptor (KGFR). 5-FU signiWcantly reduced the expression of KGF, did not change KGFR expression, and signiWcantly reduced the Ki-67 labeling index, relative to the control group. The eVect of 5-FU on cholesteatoma seems to be mediated, at least in part, through downregulation of KGF in stromal cells and reduction of the proliferative activity of epithelial cells.
Introduction
Middle ear cholesteatoma is a pathological condition associated with otitis media [1, 2] accompanying hearing loss and occasionally facial palsy [3] , and recurrence after surgical treatment is very common [4] . Cholesteatoma is a tumor-like mass consisting of keratinizing squamous epithelium, usually occurring in the middle ear and mastoid. Our understanding of the molecular mechanism underlying the pathogenesis of cholesteatoma is limited, but an important pathological process in this entity is active proliferation of epithelial cells [5] [6] [7] , which is thought to be stimulated by various growth factors [8] [9] [10] . Among the latter, we focused in our previous study on the keratinocyte growth factor (KGF), and we indicated the possible involvement of both KGF and its receptor (KGFR) in enhanced epithelial cell proliferative activity and recurrence of cholesteatoma [11] . KGF, a unique member of the Wbroblast growth factor (FGF) family, is a mesenchymal cell-derived paracrine mediator of epithelial cell growth [12] , and its receptor KGFR is activated by binding to KGF, triggering a signal transduction pathway, which in turn stimulates the proliferation of epithelial cells [13] . Therefore, it seems quite reasonable to assume that KGF and KGFR play an important role in the proliferative stage of cholesteatoma.
While the pathogenesis of cholesteatoma has been analyzed and inXuence of cytokine has been emphasized, unfortunately, there was no suitable therapy except surgery. On the other hand, in 1985, Smith [14] , treated cholesteatoma with 5-Xuorouracil (5-FU) as an agent to suppress its abnormal proliferation, and reported its clinical eVect. Furthermore, Wring et al. [15] conWrmed the eYcacy of 5-FU in animal experiments and Sala [16] and Iwanaga et al. [17] reconWrmed its clinical eYcacy and safety. Takahashi et al. [18] also tried this treatment for cholesteatoma using commercially available 5-FU topical cream, and reported its usefulness. However, the mechanism of action of 5-FU on cholesteatoma remains poorly understood.
In the present study, we examined the eVect of 5-FU on the expression of KGF, KGFR and epithelial cell proliferative activity (Ki-67) in attic cholesteatomas that contain the head of the malleus and the body of the incus by immunohistochemistry.
Materials and methods

Cases and cholesteatoma specimens
The study subjects consisted of 77 ears with attic cholesteatoma. The age of the patients ranged from 10 to 85 years (average, 50 years). They represented all cases that were treated surgically at the Department of Otolaryngology, Nagasaki University Hospital between February 2002 and May 2006 (Table 1 ). Before surgery, 12 patients were treated with 5-FU. After cleaning the debris within or on the surface of the cholesteatoma as much as possible, 2-3 mm 3 of 5% 5-FU topical cream (Kyowa, Roche) was applied to the outer surface of cholesteatoma, transmeatally under the microscope, two to three times with an interval of 2 weeks (5-FU group). The other 65 cholesteatoma cases did not receive 5-FU treatment and served as the control group. For the control group, 36 patients were males and 29 patients were females, while for the 5-FU group, 10 patients were males and 2 patients were females. The average age was 59 years for the control group and 42 for the 5-FU group (Table 1) . In both groups, cholesteatoma tissue was removed during surgery, and a part of it was sampled mainly from around the attic for this study.
The study protocol was approved by the Human Ethics Review Committee of Nagasaki University School of Medicine and a signed consent form was obtained from each subject for 5-FU treatment and surgery.
Tissue preparation
Cholesteatoma specimens were obtained during surgery from all 77 patients and used for immunohistochemistry. Each of the 77 specimens was Wxed overnight in 10% buVered formalin at room temperature (RT) and embedded in paraYn. Serial sections were cut to 4-m thickness, and then placed onto 3-aminopropyltriethoxysilane-coated glass slides and adjacent sections were stained with hematoxylin and eosin and processed for immunohistochemical analysis of KGF, KGFR and Ki-67.
Immunohistochemistry for KGF and KGFR
Enzyme immunohistochemistry was performed to examine the expression of KGF and KGFR in tissue sections. Polyclonal antibodies against KGF and KGFR were prepared by immunization of rabbits against synthetic peptides in cooperation with Nichirei Co. (Tokyo, Japan). Cholesteatoma paraYn sections were deparaVinized with toluene and rehydrated by serially graded ethanol solutions. For KGFR detection, the slides were pretreated with 0.2% TritonX-100 in phosphate buVered saline (PBS) for 15 min at RT. After inactivation of endogenous peroxidase activity with 0.3% H 2 O 2 in methanol, the sections were preincubated with 500 g/ml normal goat IgG and 1% bovine serum albumin in PBS for 1 h to block nonspeciWc reaction with the Wrst antibody. Then, the sections were incubated overnight with the Wrst antibody at 0.5 g/ml anti-KGF antibody or 8,000-fold dilution of anti-KGFR antisera, washed three times with 0.075% Brij 35 in PBS, and reacted with horseradish peroxidase (HRP)-goat anti-rabbit IgG for 1 h. After the slides were washed with 0.075% Brij 35 in PBS, HRP sites were visualized with 3,3Ј-diaminobenzidine4HCl (DAB), Ni, Co and H 2 O 2 . For negative control, normal rabbit IgG or normal rabbit serum was used instead of the Wrst antibodies, respectively, in every experiment.
IdentiWcation of proliferating cells
The nuclear antigen associated with cell proliferation was immunohistochemically detected using anti-Ki-67 antibody. For this purpose, sections were Wrst deparaVinized, then the slides were autoclaved in 10 mM citrate buVer (pH 6.0) for 15 min at 120°C and processed in a manner similar to that described above, except for the concentration of anti-Ki-67 antibody (1:100) and the use of HRP-goat 
Results
Immunohistochemical localization of KGF and KGFR
In cholesteatoma tissues of the control group, intense staining for KGF was detected in stromal cells (Fig. 1a) , which were mostly Wbroblasts and inWltrating lymphocytes. In addition, a few KGF-positive cells were found in the epithelium. KGFR was predominantly found in the cells of the spinous layer and also in some basal and granular cells. The staining was exclusively localized to the plasma membrane (Fig. 1b) . In addition, when the sections were reacted with preimmune normal rabbit serum instead of the Wrst antibody, no staining was found (data not shown). In 7 out of the 12 specimens of the 5-FU group, KGF was detected in a few stromal Wbroblasts (data not shown), but in 5 out of 12 specimens, KGF was not detected in any stromal Wbroblasts (Fig. 2a) . KGFR was found in epithelial cells in 6 out of 12 specimens of the 5-FU group (data not shown), while the remaining 6 cases were negative for the receptor (Fig. 2b) . The percentage of KGF-positive cases among the control group (90.5%, 57/63 specimens) was signiWcantly higher than that of 5-FU group (58.3%, 7/12, P < 0.05) (Fig. 3) . On the other hand, 34 out of 56 (60.7%) specimens of the 5-FU group were positive for KGFR while 6 out of 12 (50.0%) specimens of the control group were scored as KGFR-positive (Fig. 4) . There was no signiWcant diVerence in the incidence of KGFR-positive specimen between the two groups (P = 0.53). Immunohistochemical analysis for Ki-67 was performed to compare the proliferative activity of cholesteatoma tissues of the 5-FU group and control group. In specimens of both groups, Ki-67-positive cells were found in the suprabasal and upper layers (Figs. 1c, 2c ). In the tissues of control group, many Ki-67-positive cells were found in the basal and spinous layers (Fig. 1c) . On the other hand, in the specimens of the 5-FU group, Ki-67-positive cells were found in the basal layer mainly (Fig. 2c) . The Ki-67 LI of the 5-FU group (37.5 § 0.2%) was signiWcantly lower than that of the control group (49.5 § 0.2%, t = 2.00, P < 0.05) (Fig. 5) .
Discussion
The major Wndings of the present study were that topical treatment of attic cholesteatoma with 5-FU cream induced: (1) signiWcant downregulation of KGF expression, (2) no change in KGFR expression, and (3) signiWcant reduction of epithelial cell proliferative activity.
In our previous study, we demonstrated that KGF was abundantly located in the granulation tissue underneath the epithelium of the cholesteatoma, which is rich in KGFR, indicating that cell proliferation in cholesteatoma is facilitated by chronic inXammation underneath the cholesteatoma epithelium [11] . The present study showed that KGF expression and Ki-67 LI of the 5-FU group were signiWcantly lower than those of the control group. What do these Wndings mean? It is possible that 5-FU is taken up directly by epithelial cells, where it induces apoptosis of these cells. Alternatively, 5-FU could reduce the expression of KGF in stromal cells through its proapoptotic activity, which in turn reduces the proliferative activity of epithelial cells. 5-FU could induce apoptosis of both epithelial cells and stromal cells and downregulate the proliferative activity of epithelial cells in cholesteatoma through the paracrine action of KGF. In all of the mechanisms, 5-FU seems to arrest the growth of cholesteatoma tissues. In fact, in the previous study Kanamaru et al. [19] detected that 5-FU downregulated the growth of tympanic membrane and 5-FU inhibited the proliferation of Wbroblasts of middle ear in a dose-dependent manner in vitro. The antiproliferative eVect of 5-FU arises from its metabolites acting as metabolic blockers that inhibit thymidylate synthetase, which converts ribonucleotides to deoxyribonucleotides, thus inhibiting DNA synthesis [20] . 5-FU acts selectively on the growth phases corresponding to DNA and RNA synthesis, respectively, in the cell cycle; therefore, the cells in the synthesis phase are aVected [20] .
5-FU did not downregulate the expression of KGFR. We postulate that the expression of KGFR in epithelial cells might serve to induce migration of epithelial cells against 5-FU-induced apoptosis.
On the other hand, the antiapoptotic eVect of KGF was previously reported in human keratinocytes [21] , and the studies suggested that KGF could forestall the ability of normal human keratinocytes to both initiate terminal diVerentiation and undergo features of apoptosis in vitro [21] . In contrast, in the present study, it seemed that the proapoptotic eVect of 5-FU was opposed by the expression of KGF in stromal cells. However, we reported previously that there was no diVerence in the number of epithelial apoptotic cells in cholesteatoma and normal skin, and postulated that the production of KGF by epithelial cells could enhance their proliferative activity in cholesteatoma rather than inhibit their apoptosis [11] .
Iwanaga et al. [17] studied the side eVects of 5-FU in animal experiments and concluded that 5-FU treatment should be only indicated for cholesteatoma without eardrum perforation or cochlear or semicircular canal Wstula. In our study, we selected only attic cholesteatomas in patients conWrmed to be free of perforation at the bottom of retraction-pockets, and none of the patients developed any 5-FU-related serious side eVect. In the present study, as a control group, we only use cholesteatoma cases, which did not receive 5-FU treatment. However, it is better to compare with immunostainings of KGF, KGFR and Ki-67of their retroauricular skins as a control in both 5-FU-treated and non-treated groups. More strictly, control sample would have been harvested from a distant place like the site of retroauricular incision.
In conclusion, we analyzed the eVects of 5-FU on the pathology and immunohistochemistry of cholesteatoma and found that this agent downregulated the expression of KGF in stromal cells of cholesteatoma and reduced the proliferative activity of epithelial cells. We believe that 5-FU treatment is eVective for attic cholesteatoma and early-stage recurrence cases. We recommend 5-FU treatment for earlystage cholesteatoma with follow-up examination including computed tomography.
